背景由慢性丙型肝炎(CHC)感染引起的肝硬化(LC)是全球主要的公共卫生问题。本研究将探讨持续丙型肝炎病毒(HCV)感染患者进行性纤维化和肝硬化的危险因素。方法在这项队列研究中,共纳入300例患者.我们收集了整个200名慢性丙型肝炎感染患者的全面诊断记录。为了比较,招募并评估了100名健康人。FibroScan(回声,巴黎,法国)评分用于对肝纤维化分期进行分类:F0-F1(无或轻度纤维化,<7kPa),F2(中度纤维化,7-8.99kPa),F3(显着纤维化,9-12.49kPa),和F4(肝硬化,≥12.5kPa)。他们的人口统计,生物化学,和血清学数据进行了评估和比较。结果大部分患者为男性(47%为女性,53%为男性)。在CHC组中,诊断平均年龄为37.68±11.57岁,而在慢性丙型肝炎相关肝硬化(CHC-LC)组中,平均年龄为48.89±12.30岁(p=0.01)。与正常人相比,CHC患者的体重指数(BMI)较高(22.37±1.89vs21.72±1.95,p=0.01),丙氨酸氨基转移酶(ALT)(36.70±7.13对82.78±82.53,p=0.01),天冬氨酸转氨酶(AST)(34.96±6.04对80.82±91.77,p=0.01)。然而,与CHC患者相比,LC患者的血小板(PLT)计数较低(1.51±0.78vs.1.7±0.41,p=0.01),肝酶较高(AST:117.7±186.9vs.80.8±91.7,p=0.01;ALT:86.71±80.24vs.82.78±82.53,p=0.01).关于回归分析,BMI较高,年龄较大,低血红蛋白(Hb),和更高的胆红素,ALT,AST,凝血酶原时间(PT)与LC相关。结论作为HCV相关性肝硬化患者管理的新方法,必须转向预防和早期干预。肥胖且血小板计数低、肝酶较高的老年CHC患者应怀疑肝硬化。
Background Liver cirrhosis (LC) caused by chronic hepatitis C (CHC) infection is a major global public health concern. This study will look at the risk factors for progressive fibrosis and cirrhosis in patients with persistent hepatitis C virus (HCV) infection. Methods In this cohort study, a total of 300 patients were included. We collected comprehensive diagnostic records for the entire study group of 200 people with chronic hepatitis C infection. For the comparison, 100 healthy people were recruited and assessed. FibroScan (Echosens, Paris, France) scores were used to categorize liver fibrosis stages: F0-F1 (no or mild fibrosis, <7 kPa), F2 (moderate fibrosis, 7-8.99 kPa), F3 (significant fibrosis, 9-12.49 kPa), and F4 (cirrhosis, ≥12.5 kPa). Their demographic, biochemical, and serological data were evaluated and compared. Results Most patients were males (47% females and 53% males). In the CHC group, the mean age of diagnosis was 37.68±11.57 years, whereas in the chronic hepatitis C-related liver cirrhosis (CHC-LC) group, the mean age was 48.89±12.30 years (p=0.01). Compared to normal individuals, CHC patients had higher body mass index (BMI) (22.37±1.89 versus 21.72±1.95, p=0.01), alanine aminotransferase (ALT) (36.70±7.13 versus 82.78±82.53, p=0.01), and aspartate aminotransferase (AST) (34.96±6.04 versus 80.82±91.77, p=0.01). However, compared to the patients with CHC, the patients with LC have lower platelet (PLT) count (1.51±0.78 versus 1.7±0.41, p=0.01) and higher liver enzymes (AST: 117.7±186.9 versus 80.8±91.7, p=0.01; ALT: 86.71±80.24 versus 82.78±82.53, p=0.01). On regression analysis, higher BMI, older age, low hemoglobin (Hb), and higher bilirubin, ALT, AST, and prothrombin time (PT) were associated with LC. Conclusion It is imperative to shift toward prevention and early intervention as the new approach to managing patients with HCV-related cirrhosis. Cirrhosis should be suspected in older patients with CHC who are obese and have low platelet counts with higher liver enzymes.